姜黄素抑制APL细胞增殖及增强ATRA诱导分化作用的实验分析-病原生物学专业论文.docxVIP

Abst Abstract IV IV ABSTRACT Acute promyelocytic leukemia (APL)is a kind of acute myeloid leukemia (AML) that were blocked at the promyelocyte stage. Research shows that 95% of APL patients have the specific fusion gene PML/RARα, and encoded PML/RARα fusion protein. PML/RARα protein could inhibit the nomal fuctions of wild type PML and RARα with dominant negative inhibition, which lead to the leukemia cell blocked at the promyelocyte stage, is considered to be the cause of the key molecules in the pathogenesis of APL. Eightys of last century, the differentiation induced therapeutic methods was used with all trans retinoic acid (ATRA) and arsenic trioxide in the treatment of the APL was the successful, which make the APL as a cured acute leukemia. But there are still 20-30% patients were relapsed or not sensitive to ATRA. Therefore, resistance or relapse after treatment by ATRA become very difficult problems in clinical treatment of APL, and to find a new approach to overcome the APL relapsed or refractory is important . Curcumin, a kind of hydrophobic phenolic compounds, which is extracted from the rhizome of Curcuma longa in plants, has been used as drug in the local pain, relieving flatulence, colic pain pattern and anger in ancient Chinese. In recent decades, the study found that, curcumin has very good curative effect on hyperlipemia, thrombosis, myocardial infarction, diabetes, rheumatoid arthritis, nervous system disease and tumors. Research shows that, curcumin could regulate protein kinase, inflammatory cytokines, transcription factors, tumor metastasis factor, growth factor, cell cycle regulatory proteins, apoptosis related proteins, receptors, and other multiple target group which treat a variety of diseases. At present, the curcumin antitumor clinical trials has completed one or two phase clinical trials in multiple research center in the world, and has passed FDA approval to enter the three phase of clinical America, therefore, curcumin is a po